Search results
Results from the WOW.Com Content Network
Also Read: Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point.
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day. Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher Skip to main content
Investors are optimistic about Exact Sciences (EXAS) on solid first-quarter performance and strategic partnerships.
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer ; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer .
Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In the latest trading session, Exact Sciences (EXAS) closed at $57.56, marking a -1.96% move from the previous day. Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know Skip to ...
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.